Abstract:
Purpose: Vitiligo is an idiopathic depigmenting skin disorder. The study compares the efficacy of topical tacrolimus 0.1% with calcipotriol/betamethasone dipropionate in vitiligo patients receiving NB-UVB treatment.Materials and methods: Forty-one adult patients with generalized type vitiligo were recruited. Patients were assigned to phototherapy and then classified into either group one (20 patients), receiving calcipotriol/betamethasone dipropionate cream (D group), or group two (21 patients), receiving tacrolimus 0.1% ointment (T group). They were followed-up at 3 and 6 months.Results: The D group witnessed an increase in the repigmentation area from 35.4% in the third month to 54.7% in the sixth month (p = 0.001) and the T group from 32.2% to 45.6% (p = 0.011). However, the differences between the treatment groups were not statistically significant. Body sites demonstrated different levels of improvement ranging from the highest in the face to the lowest in the Hand & Feet with the other body sites in between. A negative correlation was identified between the duration since diagnosis and the response to D treatment (3 months: r = -0.612, p = 0.007; 6 months: r = -0.755, p = 0.001).Conclusions: Although both combinations are efficacious, they did not significantly differ in efficacy at three and six months follow-up points.Clinical trial registration: The study was registered at clinicaltrials.gov (NCT04440371).
摘要:
目的:白癜风是一种特发性皮肤色素脱失性疾病。该研究比较了接受NB-UVB治疗的白癜风患者局部使用0.1%他克莫司与卡泊三醇/二丙酸倍他米松的疗效。材料与方法:纳入41例成人广泛性白癜风患者。患者被分配到光疗,然后分为任何一组(20名患者),接受卡泊三醇/二丙酸倍他米松乳膏(D组),或第二组(21名患者),接受0.1%他克莫司软膏(T组)。随访3个月和6个月。结果:D组的色素沉着面积从第三个月的35.4%增加到第六个月的54.7%(p=0.001),T组的色素沉着面积从32.2%增加到45.6%(p=0.011)。然而,治疗组之间的差异无统计学意义.身体部位表现出不同程度的改善,从面部最高到手脚最低,其他身体部位介于两者之间。自诊断以来的持续时间与对D治疗的反应之间存在负相关(3个月:r=-0.612,p=0.007;6个月:r=-0.755,p=0.001)。结论:尽管两种组合都有效,在3个月和6个月随访时,两组患者的疗效无显著差异.临床试验注册:该研究在clinicaltrials.gov(NCT04440371)注册。